Long noncoding RNA CERS6-AS1 functions as a malignancy promoter in breast cancer by binding to IGF2BP3 to enhance the stability of CERS6 mRNA

被引:61
作者
Bao, Gang [1 ]
Huang, Jianjun [1 ]
Pan, Wei [2 ]
Li, Xing [2 ]
Zhou, Tian [1 ]
机构
[1] Guizhou Med Univ, Breast Surg, Affiliated Hosp, 28 Guiyi St, Guiyang 550004, Guizhou, Peoples R China
[2] Guizhou Med Univ, Inspect Inst, Guiyang, Guizhou, Peoples R China
来源
CANCER MEDICINE | 2020年 / 9卷 / 01期
关键词
breast cancer; CERS6; CERS6-AS1; IGF2BP3; CELL-GROWTH; PROTEIN; SPHINGOLIPIDS; PATHOGENESIS;
D O I
10.1002/cam4.2675
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Breast cancer (BC) leads to the highest mortality in women worldwide, characterized by inevitable proliferation and metastasis of BC cells. Mounting evidence confirm that lncRNAs play a significant role in the tumorigenesis and development of BC. lncRNA CERS6-AS1 is a novel discovery, and its role and molecular mechanism in BC has not been studied. In this study, it was discovered that CERS6-AS1 was overexpressed in BC tissues and cells. CERS6-AS1 accelerated cell proliferation and suppressed cell apoptosis in BC. Moreover, molecular mechanism exploration uncovered that there was a positive association between CERS6 and CERS6-AS1 (or IGF2BP3) expression in BC. Furthermore, IGF2BP3 serves as a RNA-binding protein for CERS6-AS1 and CERS6-AS1 promoted CERS6 mRNA stability by binding to IGF2BP3. In the end, rescue experiments verified that overexpression of CERS6 rescues the inhibition of CERS6-AS1 deficiency on BC progression in vitro and vivo. Taken together, these evidences suggested that CERS6-AS1 promoted the progression of BC by binding to IGF2BP3 and thus enhancing the stability of CERS6 mRNA, providing a new underlying therapeutic target for BC to improve prognosis.
引用
收藏
页码:278 / 289
页数:12
相关论文
共 34 条
[11]   Emerging roles of RNA and RNA-binding protein network in cancer cells [J].
Kim, Mee Young ;
Hur, Jung ;
Jeong, Sunjoo .
BMB REPORTS, 2009, 42 (03) :125-130
[12]   Altered sphingolipid metabolism in human endometrial cancer [J].
Knapp, Pawel ;
Baranowski, Marcin ;
Knapp, Malgorzata ;
Zabielski, Piotr ;
Blachnio-Zabielska, Agnieszka U. ;
Gorski, Jan .
PROSTAGLANDINS & OTHER LIPID MEDIATORS, 2010, 92 (1-4) :62-66
[13]   Long noncoding RNA OCC-1 suppresses cell growth through destabilizing HuR protein in colorectal cancer [J].
Lan, Yang ;
Xiao, Xuewei ;
He, Zhengchi ;
Luo, Yu ;
Wu, Chuanfang ;
Li, Ling ;
Song, Xu .
NUCLEIC ACIDS RESEARCH, 2018, 46 (11) :5809-5821
[14]   The role of the oncofetal IGF2 mRNA-binding protein 3 (IGF2BP3) in cancer [J].
Lederer, Marcell ;
Bley, Nadine ;
Schleifer, Christian ;
Huettelmaier, Stefan .
SEMINARS IN CANCER BIOLOGY, 2014, 29 :3-12
[15]   Silencing lnc-ASAH2B-2 Inhibits Breast Cancer Cell Growth via the mTOR Pathway [J].
Li, Jingjing ;
Zhang, Jing ;
Jin, Liang ;
Deng, Heran ;
Wu, Jiannan .
ANTICANCER RESEARCH, 2018, 38 (06) :3427-3434
[16]   Long non-coding RNA FGF13-AS1 inhibits glycolysis and sternness properties of breast cancer cells through FGF13-AS1/IGF2BPs/Myc feedback loop [J].
Ma, Fei ;
Liu, Xu ;
Zhou, Shibo ;
Li, Wenjie ;
Liu, Chunxiao ;
Chadwick, Michelle ;
Qian, Cheng .
CANCER LETTERS, 2019, 450 :63-75
[17]   Signal transduction of stress via ceramide [J].
Mathias, S ;
Peña, LA ;
Kolesnick, RN .
BIOCHEMICAL JOURNAL, 1998, 335 :465-480
[18]   Oncofetal protein IGF2BP3 facilitates the activity of proto-oncogene protein eIF4E through the destabilization of EIF4E-BP2 mRNA [J].
Mizutani, R. ;
Imamachi, N. ;
Suzuki, Y. ;
Yoshida, H. ;
Tochigi, N. ;
Oonishi, T. ;
Suzuki, Y. ;
Akimitsu, N. .
ONCOGENE, 2016, 35 (27) :3495-3502
[20]   Biologically active sphingolipids in cancer pathogenesis and treatment [J].
Ogretmen, B ;
Hannun, YA .
NATURE REVIEWS CANCER, 2004, 4 (08) :604-616